核ホルモン受容体活性化による転移性メラノーマの幅広いスペクトルの治療抑制
Nora Pencheva1, Colin G Buss1, Jessica Posada1
1Laboratory of Systems Cancer Biology, Rockefeller University, New York, NY 10065, USA.
Cell
|March 4, 2014
まとめ
肝臓X核ホルモン受容体 (LXR) をアゴニストで標的にすると,メラノーマの転移を抑制する. LXRβの活性化は,アポリポプロテイン-Eを介して,腫瘍の成長を抑制し,生存を向上させ,新しい治療戦略を提供します.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- 薬理学 薬理学とは
背景:
- メラノーマの転移は,限られた治療選択肢を持つ重要な臨床的課題であり続けている.
- 肝臓X核ホルモン受容体 (LXR) 経路は,様々な細胞プロセスに関与していますが,メラノーマにおけるその役割は完全に解明されていません.
研究 の 目的:
- メラノーマ転移の予防と治療のための潜在的な治療標的として,肝臓X核ホルモン受容体 (LXR) を調査する.
- メラノーマの進行と転移に対するLXRの影響の基礎にある分子メカニズムを解明する.
主な方法:
- メラノーマモデルにおけるLXRアゴニストの薬理学的投与.
- 遺伝子発現とタンパク質分析を含む分子分析.
- LXRβ操作を含む遺伝子研究.
- 腫瘍の成長,侵入,血管新生および転移の評価 in vivo.
- 標準的なメラノーマ治療と併用療法の評価.
主要な成果:
- 口服のLXRアゴニストは,メラノーマの侵入,血管新生,腫瘍の進行,転移を著しく抑制しました.
- LXRβの活性化は,腫瘍およびストロマ細胞におけるアポリポプロテイン-E (ApoE) を誘導する主要なメディエーターとして特定されました.
- LXRβアゴニズムは,様々なメラノーマの変異背景と長期生存において有効性を示した.
- LXRβの活性化により,ダカルバジン,B-Raf阻害剤,抗CTLA-4抗体との相乗効果が示され,耐性を克服した.
結論:
- 肝臓X核ホルモン受容体 (LXR),特にLXRβは,メラノーマの有効な治療標的である.
- LXRβの活性化は,ApoE誘導により,メラノーマの転移と腫瘍の成長を効果的に抑制します.
- LXRβターゲティングは有望な戦略であり,現在のメラノーマ治療法を強化し,薬剤耐性を克服する可能性がある.
関連する概念動画
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Transducer Mechanism: Nuclear Receptors
6.6K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
6.6K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K


